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Abstract
Background: Patients with diabetes are at an increased risk of readmission and mortality when discharged from
hospital. Existing research identifies statistically significant risk factors that are thought to underpin these outcomes.
Increasingly, these risk factors are being used to create risk prediction models, and target risk modifying
interventions. These risk factors are typically reported in the literature accompanied by unstandardized effect sizes,
which makes comparisons difficult. We demonstrate an assessment of variation between standardised effect sizes
for such risk factors across care outcomes and patient cohorts. Such an approach will support development of
more rigorous risk stratification tools and better targeting of intervention measures.
Methods: Data was extracted from the electronic health record of a major tertiary referral centre, over a 3-year
period, for all patients discharged from hospital with a concurrent diagnosis of diabetes mellitus. Risk factors
selected for extraction were pre-specified according to a systematic review of the research literature. Standardised
effect sizes were calculated for all statistically significant risk factors, and compared across patient cohorts and both
readmission & mortality outcome measures.
Results: Data was extracted for 46,357 distinct admissions patients, creating a large dataset of approximately 10,
281,400 data points. The calculation of standardized effect size measures allowed direct comparison. Effect sizes
were noted to be larger for mortality compared to readmission, as well as for being larger for surgical and type 1
diabetes cohorts of patients.
Conclusions: The calculation of standardised effect sizes is an important step in evaluating risk factors for
healthcare events. This will improve our understanding of risk and support the development of more effective risk
stratification tools to support patients to make better informed decisions at discharge from hospital.
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Background
Increasing numbers of hospital inpatients have a co-
existent diagnosis of diabetes [1]. These patients are at
an increased risk of both readmission [2] and mortality
[3, 4]. Multiple studies have been performed aiming to
identify statistically significant risk factors for poor out-
comes, when patients with diabetes are discharged from
hospital [5, 6]. These studies typically identify risk fac-
tors for generalised populations of inpatients with dia-
betes [7, 8], or for an individual specific cohorts who
may have been admitted for a particular condition or
group of conditions [9–11]. Almost universally, these
studies report statistically significant risk factors for an
individual outcomes (either readmission or mortality)
and report unstandardized effect size measures, usually
as odds ratios.
The use of unstandardized effect size measures that re-
port only on individual outcomes for individual patient
cohorts, makes effect size comparisons between groups
difficult. Comparisons between studies are additionally
difficult as, unlike clinical trials, extracted electronic
health record data is rarely made available as supple-
mentary material to research articles, due to the risk of
inadvertently compromising anonymity of the data. Fur-
thermore, whilst standardised effect sizes can be calcu-
lated if both the sample size and standard deviation are
given with unstandardised effect statistics in articles, it is
recognised that this information is too often incomplete
and can be a laborious process across multiple studies
even if it is available [12].
This represents a key challenge in identifying optimal
targets and outcome measures for the delivery of inter-
ventions to improve the discharge process from hospital
for patients with diabetes. In particular, attempts to cre-
ate risk stratification tools for patients with diabetes at
discharge have only had limited success, often reporting
only moderate area under the curve (AUC) values and
restricted predictive values [13, 14].
Standardised effect size calculations allow the direct
comparison between risk factors, outcomes and cohorts.
Similar to other statistical tests, there are a range of ef-
fect size statistics available, with well over 60 reported in
the literature [15]. The appropriate standardised effect
size statistic needs to be selected relevant to the vari-
ables in question, with d statistics (such as Cohen’s d or)
appropriate for continuous dependant variables & pre-
dictors, whilst differing tests are relevant for effect size
estimates related to categorical date (such as Phi or
Cramér’s V) [16].
Effect sizes are descriptive statistics that support both
clinicians and researchers to interpret study findings.
The interpretation of effect sizes can be done in isolation
against pre-defined published levels of effect or “rules of
thumb” [17]. Table 1 demonstrate published rules of
thumb for Cohen’s d [18] and Phi statistics [19, 20]. Im-
portantly however, the importance of any effect is
dependent on what is being studied, with for instance
very small effect sizes being important in certain circum-
stances (for example life threating situations) [21]. Effect
sizes statistics are also particularly valuable when looking
to make comparisons, for example between different
predictors, cohorts or variables and in is primarily in this
context that standardised effect sizes have utility in con-
sidering risk predictors for negative clinical outcomes.
In this study, we extract data from a large tertiary re-
ferral centre in order to calculate standardised effect
sizes for pre-specified risk factors, across outcome mea-
sures and across patient cohorts. This research demon-
strates the importance of calculating standardised effect
sizes, a practice more typical in the psychological litera-
ture than medical literature. It further demonstrates im-
portant variation in risk at discharge from hospital for
patients with diabetes.
Methods
The study adopted a retrospective evaluation of data ex-
tracted from electronic health record (EHR) of a large
tertiary referral centre, in the West Midlands region of
the United Kingdom, for all adult patients discharged
from University Hospitals Coventry and Warwickshire
NHS Trust with a diagnosis of diabetes, over a 3-year
period. Data were extracted for an exemplar set of 10
pre-specified risk factor variables, these variables were
selected based on both pre-specification from the pub-
lished research literature [22], and the ease of which data
for these variables can be extracted from inpatient elec-
tronic health records. Ease of extraction considered to
ensure the results are generalizable to other healthcare
organisations internationally. The selected extracted var-
iables and are listed in Table 2. Outcome variable data
were extracted for hospital readmission within 30 days
and mortality within 180 days of hospital discharge.
The diagnosis of diabetes was taken from the coding
of patients at discharge and, thus, if there was discrep-
ancy in the diagnosis within the record, the latest
Table 1 “Rules of thumb for interpreting effect sizes”
Cohen’s d Phi Coefficent
Effect Size d value Effect Size d value
Very small 0.01 Negligible 0.00 to < 0.10
Small 0.2 Weak 0.10 to < 0.20
Medium 0.5 Moderate 0.20 to < 0.40
Large 0.8 Relatively strong 0.40 to < 0.60
Very large 1.2 Strong 0.60 to < 0.80
Huge 2 Very strong 0.80 to < 1.00
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diagnosis of diabetes at discharge was used. Maternity
patients were excluded from the study, due to the differ-
ing nature of maternity care and readmission patterns.
Patients discharged within the last 6 months of the study
period were not evaluated as index patients, to ensure
that all patients had a full period of 6 months follow up
on the electronic health record to assess for the outcome
measures of interest.
The association between risk factor variables and out-
comes of interest was analysed using Chi Squared Tests
for categorical variables and Student’s t-Test for con-
tinuous variables, following adequate assessment for
skew and kurtosis to ensure normality. an absolute skew
value larger than 2 or an absolute kurtosis (proper) lar-
ger than 7 may be used as reference values for determin-
ing substantial non-normality [23].
A p-value of < 0.05 was considered significant. Stan-
dardised size was evaluated using Phi coefficient for cat-
egorical variables and Cohen’s D for continuous
variables. The statistical significance and effect size was
evaluated for the following patient cohorts: all patients
discharged with a diagnosis of diabetes; all emergency
admissions discharged with a diagnosis of diabetes; all
emergency admissions discharged with a diagnosis of
Type 2 Diabetes; all emergency admissions discharged
with a diagnosis of type 1 diabetes; all elective admis-
sions discharged with a diagnosis of diabetes; all elective
admissions discharged with a diagnosis of type 2 dia-
betes; all elective admissions discharged with a diagnosis
of type 2 diabetes; all patients with diabetes discharged
from surgical care; all patients with type 1 diabetes dis-
charged from surgical care; and all patients discharged
with type 2 diabetes from surgical care.
All statistical testing was performed using Microsoft
Excel 2016 and IBM’s SPSS v24.
Ethical approval was granted by the local NHS Trust
Research Ethics Committee, at University Hospitals
Coventry & Warwickshire NHS Trust through the
Governance arrangements for Research Ethics Commit-
tee Process [Study Ref: GF0220 & GF0335]. Approval
was also granted through the University of Warwick’s
Biomedical & Scientific Research Ethics Committee
[Study Ref: REGO-2017-2114].
Results
Data was extracted for 46,367 distinct patient episodes
resulting in discharge from hospital, over the study
period, with a diagnosis of diabetes. Table 3 demon-
strates the number of patients in each cohort. Table 4 il-
lustrates the statistical significance of each risk factor in
relation to readmission per patient cohort, separated
into categorical risk factor variables (evaluated with the
Chi Squared Test) and continuous variables (evaluated
using student’s t-test) for readmission. Table 5 similarly
demonstrates statistical significance testing for mortality.
Table 6 illustrates the standardised effect sizes of each
risk factor related to readmission per patient cohort,
separated again into categorical risk factors (evaluated
using Phi coefficient) and continuous risk factors (evalu-
ated using Cohen’s D). Table 7 illustrates effect sizes in
relation to mortality at 180 days.
Statistically significant associations with readmission at
30 days were found for 46 cohort/risk factors combina-
tions, with 61 statistically significantly associations for
mortality at 180 days. Following expectations, the effect
size of most risk factors individually on outcomes was
small. However, there was significant variation in effect
size between risk factors, cohorts and outcome mea-
sures. The mean average effect size for categorical values
considering readmission (Phi Coefficient) was 0.05, with
the mean average effect size for continuous variables be-
ing (Cohen’s D) 0.23. Mean average effect size for cat-
egorical values, considering mortality, was 0.06 (Phi
coefficient) and for continuous variables 0.81 (Cohen’s
D). Effect sizes were notably larger for surgical cohorts
of patients, in particular surgical patients with T1DM.
Table 3 Patient cohorts and sample size
Patient Cohort Number of patients
in sample
All diabetes discharges 46,367
Emergency admission discharges with diabetes 20,140
Elective admission discharges with diabetes 23,379
Emergency admission surgical discharges 3032
Emergency admission medical discharges 14,250
All surgical care discharges with type 1 diabetes 399
All surgical care discharges with type 2 diabetes 2547
All medical care discharges with type 1 diabetes 1455
All medical care discharges with type 2 diabetes 12,498
Table 2 Readily extractable pre-specified risk factors
Selected Risk Factors
Age
Sex
Co-morbidity burden
Previous DKA
Dementia
DSN review
T1DM
T2DM patients
Unknown diabetes type
Weekend Discharged
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Discussion
We demonstrate that there is substantial variation in the
effect sizes, regarding risk factors related to poor out-
comes at discharge from hospital for patients with dia-
betes. Whilst a large number of candidate risk factors
have been identified as statistically significant, there is
variation in the effect sizes between individual risk fac-
tors. Typically, effect sizes for mortality were greater
than effect sizes for readmission, suggesting that using
the risk factors described here, it may be easier to pre-
dict risk related to mortality than readmission. This is
particularly interesting, given that readmission is most
commonly used as the maker of the success of the dis-
charge process and a typical target for risk predication
modelling and risk reduction interventions.
There is also substantial variation in both the statis-
tical significance and effect size of individual risk factors
between individual cohorts of patients with diabetes, as
well as the overall combined effect sizes between indi-
vidual patient cohorts. This suggests, again, that risk pre-
diction may be easier for some cohorts of patients,
particularly those with Type 1 Diabetes & those attend-
ing for surgery. The ability, with which we are able to
predict risk from known risk factors, is important in the
development and appropriateness of developing risk pre-
diction tools, but also in targeting interventions to those
most at need. The targeting of interventions, supported
by evidence-based discussions of risk with patients, is es-
sential to individualised sustainable healthcare.
This study does not aim to provide a comprehensive
assessment of effect sizes for every patient cohort with
diabetes at discharge from hospital, or for every known
risk factor for poor outcomes. Rather, we demonstrate
the substantial variations of standardised effect sizes
Table 4 Assessment of statistically significant association between risk factors and readmission at 30 days. [Shaded cells reflect lack
of statistical significant value of p < 0.05]
Assessment of statistically
significant association
between risk factors and
readmission at 30 days.
Statistical
Test
All
diabetes
discharges
Emergency
admission
discharges
Elective
admission
discharges
Emergency
admission
surgical
discharges
Emergency
admission
medical
discharges
T1DM
Surgical
patients
T2DM
Surgical
patients
T1DM
Medical
patients
T2DM
Medical
patients
Age TTEST < 0.01 0.33 < 0.01 0.09 0.08 < 0.01 0.6 0.07 0.94
Sex CHISQ 0.01 0.04 0.62 0.06 0.39 < 0.01 0.42 < 0.01 0.16
Co-morbidity burden TTEST < 0.01 < 0.01 < 0.01 0.56 < 0.01 < 0.01 < 0.01 0.07 < 0.01
Previous DKA CHISQ < 0.01 < 0.01 < 0.01 < 0.01 0.68 < 0.01 0.57 0.19 0.75
Dementia CHISQ < 0.01 < 0.01 0.05 0.09 < 0.01 0.27 0.12 0.34 0.02
DSN review CHISQ < 0.01 < 0.01 < 0.01 0.18 < 0.01 0.05 0.38 < 0.01 < 0.01
T1DM CHISQ < 0.01 < 0.01 < 0.01 < 0.01 0.03 NA NA NA NA
T2DM patients CHISQ < 0.01 0.10 < 0.01 0.06 0.46
Unknown diabetes type CHISQ < 0.01 < 0.01 < 0.01 0.15 < 0.01
Weekend Discharged CHISQ < 0.01 0.06 < 0.01 0.01 < 0.01 0.44 0.03 0.29 0.36
Table 5 Assessment of statistically significant association between risk factors and mortality at 180 days. . [Shaded cells reflect lack of
statistical significant value of p < 0.05]
Assessment of statistically
significant association
between risk factors and
mortality at 180 days.
Statistical
Test
All
discharges
Emergency
admission
discharges
Elective
admission
discharges
Emergency
admission
surgical
discharges
Emergency
admission
medical
discharges
T1DM
Surgical
patients
T2DM
Surgical
patients
T1DM
Medical
patients
T2DM
Medical
patients
Age TTEST < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Sex CHISQ < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 0.92 0.60 0.07 < 0.01
Co-morbidity burden TTEST < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Previous DKA CHISQ < 0.01 < 0.01 < 0.01 0.20 < 0.01 0.01 0.65 < 0.01 < 0.01
Dementia CHISQ < 0.01 < 0.01 0.40 < 0.01 < 0.01 < 0.01 0.01 < 0.01 < 0.01
DSN review CHISQ < 0.01 0.02 < 0.01 < 0.01 < 0.01 0.80 0.05 < 0.01 0.31
T1DM CHISQ < 0.01 0.09 0.14 0.34 < 0.01 NA NA NA NA
T2DM patients CHISQ < 0.01 < 0.01 0.01 < 0.01 < 0.01
Unknown diabetes type CHISQ 0.7 0.43 < 0.01 0.09 0.82
Weekend Discharged CHISQ < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 0.58 0.34 0.12 < 0.01
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between risk factors, outcomes and patient cohorts. It is
important to note that there are a number of different
effect size measures that could be used, Cohen’s D and
Phi were selected as being widely used effect size mea-
sures and their suitability for use alongside statistical sig-
nificance measures. This, therefore, lays important
foundations for future research looking to explore indi-
vidual risk factors, outcomes or cohorts in more depth,
before possible future development of rigorous risk pre-
diction models.
The study has a number of limitations. Firstly it is
based only at a single centre, albeit with a large patient
population over a significant period of time. Secondly,
we have not attempted to control individual risk factors
at this stage; this approach is however representative of
the many studies identifying new risk factors and subse-
quently reporting with unstandardized effect sizes. It
must be remembered that this is an exemplar paper
demonstrating the utility of standardised effect sizes and
the ability to predict risk may vary depending on other
risk factors selected or cohorts analysed.
When considering the utility of standardised effect
sizes it is notable that we have used two different ef-
fect size statistics (Cohen’s d & Phi coefficient), whilst
the primary aim of using standardised effect size sta-
tistics is to enable comparison the outputs of the two
statistical methods cannot be directly compared due
to variations in the “rules of thumb” for their inter-
pretation. Whilst some processes to enable conversion
between effect size statistics have been published,
there is no accepted approach to converting between
all effect size statistics [16].
Conclusions
We demonstrate the calculation of standardised effect
sizes for risk factors related to poor outcomes when
Table 6 Assessment of standardised effect sizes for statistically significant risk factors for readmission at 30 days. [Shaded cells did
not reach statistical significant in Table 4]
Assessment of standardised
effect size between risk
factors and readmission at
30 days.
Statistical
Test
All
diabetes
discharges
Emergency
admission
discharges
Elective
admission
discharges
Emergency
admission
surgical
discharges
Emergency
admission
medical
discharges
T1DM
Surgical
patients
T2DM
Surgical
patients
T1DM
Medical
patients
T2DM
Medical
patients
Age Cohens D 0.08 0.16 0.45
Sex Phi −0.01 − 0.01 − 0.10 0.07
Co-morbidity burden Cohens D − 0.18 − 0.11 − 0.37 − 0.12 0.39 − 0.17 − 0.18
Previous DKA Phi − 0.10 − 0.03 − 0.10 − 0.08 − 0.17
Dementia Phi 0.03 0.03 0.01 0.03 0.06
DSN review Phi −0.03 0.04 0.02 0.07 −0.11 0.12
T1DM Phi −0.06 −0.03 − 0.05 −0.06 − 0.02 NA NA NA NA
T2DM patients Phi 0.02 0.03
Unknown diabetes type Phi 0.03 0.03 0.03 0.03
Weekend Discharged Phi −0.01 0.03 0.05 − 0.03 0.04
Table 7 Assessment of standardised effect size for statistically significant risk factors for mortality at 180 days [Shaded cells did not
reach statistical significance in Table
Assessment of standardised
effect size between risk
factors and mortality at
180 days
Statistical
Test
All
diabetes
discharges
Emergency
admission
discharges
Elective
admission
discharges
Emergency
admission
surgical
discharges
Emergency
admission
medical
discharges
T1DM
Surgical
patients
T2DM
Surgical
patients
T1DM
Medical
patients
T2DM
Medical
patients
Age Cohens D −0.75 −0.71 −0.45 − 0.87 −0.69 −1.38 − 0.78 −1.64 −0.56
Sex Phi −0.03 −0.03 − 0.03 −0.03 − 0.03 −0.03
Co-morbidity burden Cohens D −0.70 −0.61 − 0.53 −0.85 − 0.57 −0.85 − 0.82 −1.27 −0.47
Previous DKA Phi 0.05 0.08 0.03 0.09 0.13 0.01 0.23 0.03
Dementia Phi −0.06 −0.05 −0.04 − 0.05 −0.16 − 0.05 −0.09 − 0.04
DSN review Phi −0.04 0.02 −0.02 − 0.04 0.05 0.16
T1DM Phi 0.04 0.09 0.09 NA NA NA NA
T2DM patients Phi −0.07 −0.08 −0.02 − 0.10 −0.08
Unknown diabetes type Phi 0.02
Weekend Discharged Phi −0.02 < 0.01 0.02 −0.03 − 0.04 − 0.04
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patients are discharge from hospital. Whilst individual
effect sizes are often small, there is substantial variability
between different risk factors, patient cohorts and out-
comes. The use of standardised effect sizes allows the
easier comparison between such groups, this in turn
may facilitate the development of better risk stratifica-
tion models and risk minimisation interventions. We
hope that, as a consequence of this paper, more studies
will look to calculate standardised effect sizes when con-
sidering risk factors, generating more directly compar-
able results and enabling more rapid translation into
changes to patient care.
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